Similarly, correction of overactive TGF-β signaling with neutralizing TGF-β antibody ameliorates osteopenia (64, 65) but does not increase bone length or improve callus formation during fracture healing in murine models of OI (64, 66), even though TGF-β regulates chondrocyte differentiation (67). This evidence concerns the gene TGFB1 and Osteopenia.